11YB image
Deposition Date 2026-03-17
Release Date 2026-09-09
Last Version Date 2026-09-09
Entry Detail
PDB ID:
11YB
Keywords:
Title:
Structure of AlphaIIbBeta3-R21C11 Fab in the near-bent conformation
Biological Source:
Source Organism(s):
Homo sapiens (Taxon ID: 9606)
Mus musculus (Taxon ID: 10090)
Expression System(s):
Method Details:
Experimental Method:
Resolution:
3.40 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Integrin alpha-IIb
Gene (Uniprot):ITGA2B
Chain IDs:A
Chain Length:1039
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Integrin beta-3
Gene (Uniprot):ITGB3
Chain IDs:B
Chain Length:788
Number of Molecules:1
Biological Source:Homo sapiens
Structural Superimposition Protein Blast
Polymer Type:polypeptide(L)
Molecule:R21C11 Fab heavy chain
Chain IDs:C (auth: H)
Chain Length:221
Number of Molecules:1
Biological Source:Mus musculus
Structural Superimposition Protein Blast
Polymer Type:polypeptide(L)
Molecule:R21C11 Fab light chain
Chain IDs:D (auth: L)
Chain Length:211
Number of Molecules:1
Biological Source:Mus musculus
Primary Citation
A monoclonal antibody to platelet alpha IIb beta 3 that inhibits protein disulfide isomerase binding and platelet aggregation.
Blood Adv 10 3172 3185 (2026)
PMID: 41779962 DOI: 10.1182/bloodadvances.2025018960

Abstact

Platelet integrin alphaIIbbeta3 plays a pivotal role in hemostasis and thrombosis. Protein disulfide isomerase (PDI) binds to alphaIIbbeta3 and mediates its activation. The binding region(s) on alphaIIbbeta3 for PDI remains to be established. We identified a new anti-alphaIIbbeta3 murine monoclonal antibody, R21C11, that inhibits PDI binding to platelets, ligand binding to alphaIIbbeta3, and platelet aggregation. R21C11 inhibited recombinant PDI binding to platelets activated with the PAR1 thrombin receptor activating peptide SFLLRN (T6). Reciprocally, PDI partially reduced R21C11 binding to platelets. PDI was translocated to the platelet surface after activation and activated platelets showed higher PDI reductase activity. R211C11 decreased both the amount of PDI and the reductase activity. R21C11 partially inhibited both fibrinogen and PAC-1 binding to alphaIIbbeta3 and platelet aggregation induced by ADP and T6. R21C11 bound slowly to unactivated platelets and more rapidly after T6 activation; eptifibatide, which induces the alphaIIbbeta3 extended-open conformation, also increased the speed of R21C11 binding. Activation also increased total R21C11 binding. Cryogenic electron microscopy single-particle analysis of the R21C11 Fab-alphaIIbbeta3 complex revealed that R21C11 binds to the beta3 beta-tail domain in both nearly bent and semiextended-closed conformations of alphaIIbbeta3. R21C11 Fab clashed with the beta3 beta-I domain in the fully bent conformation, accounting for the slow binding rate of R21C11. These data are consistent with R21C11 inhibiting PDI binding by steric hindrance and the activation dependence of PDI binding. Taken together, these data suggest that the beta-tail domain and/or neighboring area is the binding site for PDI on integrin alphaIIbbeta3.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
Feedback Form
Name
Email
Institute
Feedback